PPARG and metabolic dysfunction-associated steatotic liver disease: A large number of recent studies suggest that PPARγ might represent a relevant clinical target for the treatment of NAFLD [63] and another set of data propose a relationship between sphingolipid biosynthesis and NAFLD [62].